JP2017502983A5 - - Google Patents

Download PDF

Info

Publication number
JP2017502983A5
JP2017502983A5 JP2016546192A JP2016546192A JP2017502983A5 JP 2017502983 A5 JP2017502983 A5 JP 2017502983A5 JP 2016546192 A JP2016546192 A JP 2016546192A JP 2016546192 A JP2016546192 A JP 2016546192A JP 2017502983 A5 JP2017502983 A5 JP 2017502983A5
Authority
JP
Japan
Prior art keywords
patient
treatment
disease state
composition
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016546192A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502983A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2014/050870 external-priority patent/WO2015049688A2/en
Publication of JP2017502983A publication Critical patent/JP2017502983A/ja
Publication of JP2017502983A5 publication Critical patent/JP2017502983A5/ja
Pending legal-status Critical Current

Links

JP2016546192A 2013-10-02 2014-10-02 不均一な腫瘍を処置するための患者特異的免疫療法 Pending JP2017502983A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361885511P 2013-10-02 2013-10-02
US61/885,511 2013-10-02
PCT/IL2014/050870 WO2015049688A2 (en) 2013-10-02 2014-10-02 Patient-specific immunotherapy for treating heterogeneous tumors

Publications (2)

Publication Number Publication Date
JP2017502983A JP2017502983A (ja) 2017-01-26
JP2017502983A5 true JP2017502983A5 (enExample) 2018-08-16

Family

ID=52779242

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016546192A Pending JP2017502983A (ja) 2013-10-02 2014-10-02 不均一な腫瘍を処置するための患者特異的免疫療法
JP2017517721A Pending JP2018500275A (ja) 2013-10-02 2015-04-08 不均一な腫瘍を処置するための患者特異的免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017517721A Pending JP2018500275A (ja) 2013-10-02 2015-04-08 不均一な腫瘍を処置するための患者特異的免疫療法

Country Status (5)

Country Link
US (2) US20160237163A1 (enExample)
EP (2) EP3052933B1 (enExample)
JP (2) JP2017502983A (enExample)
CN (2) CN106133521A (enExample)
WO (2) WO2015049688A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9576108B2 (en) * 2012-02-02 2017-02-21 Brainlab Ag Method for determining an infusion parameter
EP3052933B1 (en) * 2013-10-02 2019-09-04 Suri Technologies Ltd. Patient-specific immunotherapy for treating heterogeneous tumors
US20190057182A1 (en) * 2015-05-22 2019-02-21 Csts Health Care Inc. Biomarker-driven molecularly targeted combination therapies based on knowledge representation pathway analysis
US11515004B2 (en) 2015-05-22 2022-11-29 Csts Health Care Inc. Thermodynamic measures on protein-protein interaction networks for cancer therapy
JP2018535202A (ja) * 2015-10-12 2018-11-29 ナントミクス，エルエルシー ネオエピトープの反復発見と適応可能な免疫療法およびその方法
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
JP6895460B2 (ja) * 2016-06-03 2021-06-30 アイメッド・バイオ・インコーポレイテッド 患者由来腫瘍スフェロイドを用いた抗体スクリーニング方法
WO2018222433A2 (en) * 2017-05-30 2018-12-06 Nant Holdings Ip, Llc Circulating tumor cell enrichment using neoepitopes
US20210217530A1 (en) * 2018-02-09 2021-07-15 Axion Research Inc. System for estimating the state of target complex system
CN113597305B (zh) * 2019-03-15 2025-03-04 舒万诺知识产权公司 使用因果模型制造生物药物
US20220268762A1 (en) * 2019-07-28 2022-08-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods, systems, and computer-readable media for predicting a cancer patient's response to immune-based or targeted therapy
JP7438693B2 (ja) 2019-09-02 2024-02-27 キヤノンメディカルシステムズ株式会社 診療支援装置
CN114829882B (zh) 2019-11-05 2023-02-28 阿比尔技术公司 植物产品中感染的预测
CN117940214A (zh) * 2021-07-08 2024-04-26 欧罗科技公司 治疗功效预测系统和方法
CN115153829A (zh) * 2022-06-23 2022-10-11 中国人民解放军空军军医大学 基于活性组织电阻抗信息非均匀重构的电脉冲消融模型精度优化方法
TWI909458B (zh) * 2024-05-17 2025-12-21 國防醫學大學 一種自體免疫疾病用藥預估方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210867A (en) * 1984-01-31 1989-01-06 Litton Bionetics Inc Tumour-specific monoclonal antibodies, production thereof and use
EP0222360A3 (en) 1985-11-12 1989-03-15 Biotherapeutics Inc. A method of producing a patient-specific cytotoxic reagent and composition
US6180357B1 (en) 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
US6871171B1 (en) * 2000-10-19 2005-03-22 Optimata Ltd. System and methods for optimized drug delivery and progression of diseased and normal cells
WO2002054171A2 (en) * 2000-12-06 2002-07-11 Biosentients, Inc. System, method, software architecture and business model for an intelligent object based information technology platform
US20070111257A1 (en) * 2005-07-07 2007-05-17 Kohne David E Improved protein expression comparison assay results and applications
KR20080073725A (ko) * 2005-11-01 2008-08-11 노파르티스 아게 항-ｃｄ40 항체의 용도
BRPI0717902A2 (pt) * 2006-12-01 2013-10-29 Medarex Inc "anticorpo monoclonal humano isolado, composição, conjugado anticorpo-molécula parceria, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para prepar um anticorpo anti-cd22, método para inibir o desenvolvimento de uma célula tumoral que expressa cd22 e método para tratar uma doença inflamatória ou autoimuneem um indivíduo"
WO2008117226A1 (en) * 2007-03-27 2008-10-02 Koninklijke Philips Electronics N.V. Drug administration based on a patient's activity status measured by acceleration sensors
UA109633C2 (uk) * 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
JP5734961B2 (ja) * 2009-05-29 2015-06-17 アスペン テクノロジー インコーポレイテッド 多変数プロセス制御においてモデルの品質を推定しモデルを適応させる装置およびその方法
EP2549399A1 (en) 2011-07-19 2013-01-23 Koninklijke Philips Electronics N.V. Assessment of Wnt pathway activity using probabilistic modeling of target gene expression
MX358728B (es) * 2012-05-02 2018-09-03 Symphogen As Composiciones de anticuerpos pan-receptor del factor de crecimiento epidermico humano (pan-her) humanizados.
KR101903315B1 (ko) 2012-07-18 2018-10-01 미쓰비시덴키 가부시키가이샤 엘리베이터 장치
WO2014036488A1 (en) * 2012-08-31 2014-03-06 Biovest International, Inc. Methods for producing high-fidelity autologous idiotype vaccines
KR20150119206A (ko) * 2013-02-15 2015-10-23 가부시키가이샤 페르세우스 프로테오믹스 항 cdh3 인간화 항체, 그의 약물 콘쥬게이트, 이들의 용도
ES2662598T3 (es) * 2013-03-08 2018-04-09 F. Hoffmann-La Roche Ag Análisis de sangre para la detección de mutaciones de EGFR
EP3052933B1 (en) * 2013-10-02 2019-09-04 Suri Technologies Ltd. Patient-specific immunotherapy for treating heterogeneous tumors

Similar Documents

Publication Publication Date Title
JP2017502983A5 (enExample)
Aznar et al. Minimizing late effects for patients with mediastinal Hodgkin lymphoma: deep inspiration breath-hold, IMRT, or both?
Ladbury et al. Impact of radiation dose to the host immune system on tumor control and survival for stage III non-small cell lung cancer treated with definitive radiation therapy
Grassberger et al. Assessing the interactions between radiotherapy and antitumour immunity
Barriger et al. Dose–volume analysis of radiation pneumonitis in non–small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel
Kong et al. Non-small cell lung cancer therapy-related pulmonary toxicity: an update on radiation pneumonitis and fibrosis
Zindler et al. The clinical utility of prognostic scoring systems in patients with brain metastases treated with radiosurgery
Brodin et al. Interactive decision-support tool for risk-based radiation therapy plan comparison for Hodgkin lymphoma
JP6917357B2 (ja) 癌治療に使用する放射標識抗体断片
Gallamini et al. Interim FDG-PET imaging in lymphoma
JP2020511406A5 (enExample)
CN106133521A (zh) 用于治疗异质肿瘤的病患特异性的免疫疗法
Ng et al. Individualized 3D reconstruction of normal tissue dose for patients with long-term follow-up: a step toward understanding dose risk for late toxicity
TW201100101A (en) DKK-1 antibodies
AU2018220126A1 (en) Stem cell enhancing therapeutics
Million et al. Radiation therapy for primary cutaneous anaplastic large cell lymphoma: an international lymphoma radiation oncology group multi-institutional experience
JP2021500916A5 (enExample)
TW202318436A (zh) 用於預測細胞激素釋放症候群之多變量模型
Hande et al. Point-A vs. volume-based brachytherapy for the treatment of cervix cancer: A meta-analysis
Jackisch et al. Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival–results from a prospective, observational study in Germany
Telarovic et al. Radiation-induced lymphopenia does not impact treatment efficacy in a mouse tumor model
Cannon et al. Metabolic imaging biomarkers of postradiotherapy xerostomia
Rosenberg et al. Survival analyses and prognosis of plasma-cell myeloma and plasmacytoma-like posttransplantation lymphoproliferative disorders
HRP20210858T1 (hr) Antitijelo za igf-1r i njegova upotreba u dijagnosticiranju karcinoma
Walker et al. Evaluating the potential for maximized T cell redistribution entropy to improve abscopal responses to radiotherapy